Agnese Piersanti

Mrs. Agnese Piersanti

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
APAgnese Piersanti
Agnese Piersanti
FGFrancesco Giurato
Francesco Giurato
CGChristian Göbl
Christian Göbl
LBLaura Burattini
Laura Burattini
Andrea TuraAndrea Tura
Andrea Tura
Micaela MorettiniMicaela Morettini
Micaela Morettini
The advancement of technology in the field of glycemic control has led to the widespread use of continuous glucose monitoring (CGM), which can be nowadays obtained from wearable devices equipped with a minimally invasive sensor, i.e., transcutaneous needle-type or implantable, and a transmitter that sends information to a receiver or smart device for data storage and display. This work aims to review the currently available software packages and tools for the analysis of CGM data. Based on the purposes of this work, 12 software packages have been identified from the literature, published until December 2021, namely: Glyculator, EasyGV, CGM-GUIDE©, GVAP, Tidepool, CGManalyzer, cgmanalysis, GLU, CGMStatsAnalyzer, iglu, rGV, cgmquantify. Comparison of available software packages and tools has been done in terms of main characteristics (i.e. publication year, presence of a Graphical User Interface, availability, open-source code, number of citations, programming language, supported devices, supported data format and organization of the data structure, documentation, presence of a toy example, video tutorial, data upload and download, measurement-units conversion), preprocessing procedures, data display options and computed metrics; also, each of the computed metrics has been analyzed in terms of its adherence to the American Diabetes Association (ADA) 2017 international consensus on CGM data analysis and the ADA 2019 international consensus on time in range. Eventually, the agreement between metrics computed by different software and tools has been investigated. On the basis of such comparison, usability and complexity of data management, as well as the possibility to perform customized or patients-group analyses, have been discussed by highlighting limitations and strengths also in relation to possible different user categories (i.e. patients, clinicians, researchers). The information provided could be useful to researchers interested in working in the diabetic research field as to clinicians and endocrinologists who need tools capable of handling CGM data effectively.

27 May 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
BSBenedetta Salvatori
Benedetta Salvatori
SWSilke Wegener
Silke Wegener
GKGrammata Kotzaeridi
Grammata Kotzaeridi
AHAnnika Herding
Annika Herding
FEFlorian Eppel
Florian Eppel
CGChristian Göbl
Christian Göbl
Aims/hypothesis: Gestational diabetes mellitus (GDM) is a heterogeneous condition. Given such variability among patients, the ability to recognise distinct GDM subgroups using routine clinical variables may guide more personalised treatments. Our main aim was to identify distinct GDM subtypes through cluster analysis using routine clinical variables, and analyse treatment needs and pregnancy outcomes across these subgroups. Methods: In this cohort study, we analysed datasets from a total of 2682 women with GDM treated at two central European hospitals (1865 participants from Charité University Hospital in Berlin and 817 participants from the Medical University of Vienna), collected between 2015 and 2022. We evaluated various clustering models, including k-means, k-medoids and agglomerative hierarchical clustering. Internal validation techniques were used to guide best model selection, while external validation on independent test sets was used to assess model generalisability. Clinical outcomes such as specific treatment needs and maternal and fetal complications were analysed across the identified clusters. Results: Our optimal model identified three clusters from routinely available variables, i.e. maternal age, pre-pregnancy BMI (BMIPG) and glucose levels at fasting and 60 and 120 min after the diagnostic OGTT (OGTT0, OGTT60 and OGTT120, respectively). Cluster 1 was characterised by the highest OGTT values and obesity prevalence. Cluster 2 displayed intermediate BMIPG and elevated OGTT0, while cluster 3 consisted mainly of participants with normal BMIPG and high values for OGTT60 and OGTT120. Treatment modalities and clinical outcomes varied among clusters. In particular, cluster 1 participants showed a much higher need for glucose-lowering medications (39.6% of participants, compared with 12.9% and 10.0% in clusters 2 and 3, respectively, p<0.0001). Cluster 1 participants were also at higher risk of delivering large-for-gestational-age infants. Differences in the type of insulin-based treatment between cluster 2 and cluster 3 were observed in the external validation cohort. Conclusions/interpretation: Our findings confirm the heterogeneity of GDM. The identification of subgroups (clusters) has the potential to help clinicians define more tailored treatment approaches for improved maternal and neonatal outcomes. Graphical

14 February 2025 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
Libera Lucia Del GiudiceLibera Lucia Del Giudice
Libera Lucia Del Giudice
APAgnese Piersanti
Agnese Piersanti
CGChristian Göbl
Christian Göbl
Laura BurattiniLaura Burattini
Laura Burattini
ATAndrea Tura
Andrea Tura
Micaela MorettiniMicaela Morettini
Micaela Morettini
Background: Poor data availability and accessibility characterizing some research areas in biomedicine are still limiting potentialities for increasing knowledge and boosting technological advancement. This phenomenon also characterizes the field of diabetes research, in which glycemic data may serve as a basis for different applications. To overcome this limitation, this review aims to provide a comprehensive analysis of the publicly available data sets related to dynamic glycemic data. Methods: Search was performed in four different sources, namely scientific journals, Google, a comprehensive registry of clinical trials and two electronic databases. Retrieved data sets were analyzed in terms of their main characteristics and on the typology of data provided. Results: Twenty-five data sets were identified including data from challenge tests (5 of 25) or data from Continuous Glucose Monitoring (CGM, 20 of 25). As for the data sets including challenge tests, all of them were freely downloadable; most of them (80%) related only to oral glucose tolerance test (OGTT) with standard duration (2 h), but varying for timing and number of collected blood samples, and variables collected in addition to glucose levels (with insulin levels being the most common); the remaining 20% of them also included intravenous glucose tolerance test (IVGTT) data. As for the data sets related to CGM, 7 of 20 were freely downloadable, whereas the remaining 13 were downloadable upon completion of a request form. Conclusions: This review provided an overview of the readily usable data sets, thus representing a step forward in fostering data access in diabetes field.


28 June 2025 in Sensors
Verified
Journal Article
Open access
PDF file
APAgnese Piersanti
Agnese Piersanti
MLMartina Littero
Martina Littero
Libera Lucia Del GiudiceLibera Lucia Del Giudice
Libera Lucia Del Giudice
Ilaria MarcantoniIlaria Marcantoni
Ilaria Marcantoni
Laura BurattiniLaura Burattini
Laura Burattini
Micaela MorettiniMicaela Morettini
Micaela Morettini
This study exploited the skin temperature signal derived from a wrist-worn wearable device to define potential digital biomarkers for glycemia levels. Characterization of the skin temperature signal measured through the Empatica E4 device was obtained in 16 subjects (data taken from a dataset freely available on PhysioNet) by deriving standard metrics and a set of novel metrics describing both the current and the retrospective behavior of the signal. For each subject and for each metric, values that correspond to when glycemia was inside the tight range (70–140 mg/dL) were compared through the Wilcoxon rank-sum test against those above or below the range. For hypoglycemia characterization (below range), retrospective behavior of skin temperature described by the metric CVT SD (standard deviation of the series of coefficient of variation) proved to be the most effective both in daytime and nighttime (100% and 50% of the analyzed subjects, respectively). On the other side, for hyperglycemia characterization (above range), differences were observed between daytime and nighttime, with current behavior of skin temperature, described by M2T (deviation from the reference value of 32 °C), being the most informative during daytime, whereas retrospective behavior, described by SDT hhmm (standard deviation of the series of means), showed the highest effectiveness during nighttime. Proposed variability features outperformed standard metrics, and in future studies, their integration with other digital biomarkers of glycemia could improve the performance of applications devoted to non-invasive detection of glycemic events.

16 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
GKGrammata Kotzaeridi
Grammata Kotzaeridi
BSBenedetta Salvatori
Benedetta Salvatori
APAgnese Piersanti
Agnese Piersanti
FHFlorian Heinzl
Florian Heinzl
SZSophie Zarotti
Sophie Zarotti
CGChristian Göbl
Christian Göbl
Background/Objectives: The classification of patients with diabetes into phenotypes with distinct risks and therapeutic needs is crucial for individualized care. We recently introduced a clustering model for gestational diabetes mellitus (GDM). This study aims to further characterize the proposed clusters and to identify cluster-specific differences in glucometabolic parameters during early pregnancy in an independent cohort. The metabolic profiles and dietary habits of GDM clusters will be compared with those of a normal glucose-tolerant (NGT) control group. Methods: 1088 women (195 who developed GDM and 893 who remained NGT) underwent a broad risk evaluation at early pregnancy. GDM patients were further categorized into the three proposed GDM subtypes (CL1 to CL3). Results: Among GDM patients, 7.7% were classified as CL1, 35.9% as CL2, and 56.4% as CL3. CL1 showed higher age, pregestational BMI, and increased glucose concentrations both at fasting and during the diagnostic oral glucose tolerance test. CL2 was characterized by elevated BMI and fasting glucose, while CL3 showed higher glucose concentrations after the oral glucose load, with BMI levels comparable to NGT mothers. Women in the CL1 group exhibited impaired insulin sensitivity and β-cell function at early pregnancy and showed elevated lipid levels. Compared to NGT women, a positive family history of diabetes was more prevalent in CL1 and CL3, but not in CL2. Dietary patterns were similar across all groups. Conclusions: Our study showed distinct alterations in glucometabolic parameters already at early pregnancy among GDM subtypes. Patients in CL1 exhibited the most unfavorable risk constellation and could benefit from lifestyle changes and nutrition therapy in early pregnancy, despite showing similar dietary patterns as the NGT group.